Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease
Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…Alzheimer’s Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study
Objective: To examine the relationship between biofluid biomarkers and post-mortem pathological findings in autopsied subjects from the Parkinson’s Progression Marker Initiative (PPMI). Background: The PPMI…Analysis of α-Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants
Objective: To assess α-synuclein seed amplification assay (αS-SAA) in cerebrospinal fluid (CSF) from a cohort of PD patients and non-manifesting carriers (NMCs) of pathogenic GBA…Synaptic density and α-synuclein oligomers in skin biopsies: differences between idiopathic and GBA-linked Parkinson’s disease
Objective: To compare α-synuclein oligomers and synaptic density (SD) in skin biopsies from PD and GBA-PD. Background: Previous research [1] reported α-synuclein oligomers within synaptic terminals of autonomic fibers in…Cognitive assessment of Parkinson’s disease carriers of the novel p.A30G mutation in the SNCA gene
Objective: The aim of the present report was to evaluate the cognitive profile of symptomatic Parkinson’s disease (PD) patients in a p.A30G SNCA genetic cohort.…The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation
Objective: We aimed to clarify the relationships between the alpha-synuclein level and abnormal oscillatory activity and their changes induced by deep brain stimulation of the…PET visualization of α-synuclein pathologies in humans using [18F]C05-05
Objective: This study aimed to visualize α-synuclein aggregates in living patients with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).…National Luxembourg Sleep Study: An enriched, at risk, prodromal Parkinson’s Disease cohort
Objective: To identify a cognitively intact enriched cohort of people with isolated rapid eye movement (iREM) sleep behaviour disorder (iRBD) and hyposmia, at risk of…A multimodal approach for diagnosis of early Multiple System Atrophy (MSA)
Objective: To describe the use of neuroimaging and fluid biomarkers to improve the diagnostic accuracy of early MSA. Background: The diagnosis of early MSA is…A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 60
- Next Page »